When I started working at Ro, we had our care verticals that were solid, predictable, and reliable. There were definitely areas that needed improvement (especially with regards to patient safety protocols and having a solid foundation in organizational policy), but there was a lot of autonomy, lots of opportunity for professional development, and honestly, for the first time ever, I felt like I was actually respected as a nurse (rather than having both patients and provider's needs/desires made priority over mine as a nurse).
...and then the GLP-1 craze came to Ro. Suddenly, we were scaling far faster and far beyond our clinical capacity; chasing medications that are just not available in the community and with no ETA for when they will be widely available; changing policies to better bolster the bottom line but calling it "winning" for the patient; changing policies that weaken patient safety, etc. The list goes on and on.
I was always highly suspicious of the Kool-Aid they were peddling but chalked it up to being unfamiliar with the technology/start-up world. Now, I cannot help but see a lot of parallels between Ro's current status and the beginning of the end for Theranos. Hopefully there is no investment fraud going on too...